JP2015524403A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524403A5
JP2015524403A5 JP2015522106A JP2015522106A JP2015524403A5 JP 2015524403 A5 JP2015524403 A5 JP 2015524403A5 JP 2015522106 A JP2015522106 A JP 2015522106A JP 2015522106 A JP2015522106 A JP 2015522106A JP 2015524403 A5 JP2015524403 A5 JP 2015524403A5
Authority
JP
Japan
Prior art keywords
seq
fusion protein
domain
functional fragment
extracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015522106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524403A (ja
JP6317739B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/065248 external-priority patent/WO2014013037A1/en
Publication of JP2015524403A publication Critical patent/JP2015524403A/ja
Publication of JP2015524403A5 publication Critical patent/JP2015524403A5/ja
Application granted granted Critical
Publication of JP6317739B2 publication Critical patent/JP6317739B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015522106A 2012-07-18 2013-07-18 短縮されたCD95−Fc変異体 Expired - Fee Related JP6317739B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12176980 2012-07-18
EP12176978 2012-07-18
EP12176980.6 2012-07-18
EP12176978.0 2012-07-18
PCT/EP2013/065248 WO2014013037A1 (en) 2012-07-18 2013-07-18 Shortened cd95-fc variants

Publications (3)

Publication Number Publication Date
JP2015524403A JP2015524403A (ja) 2015-08-24
JP2015524403A5 true JP2015524403A5 (cg-RX-API-DMAC7.html) 2016-08-12
JP6317739B2 JP6317739B2 (ja) 2018-04-25

Family

ID=48794121

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015522107A Active JP6231562B2 (ja) 2012-07-18 2013-07-18 CD95−Fcアイソフォームの混合物を含む組成物
JP2015522106A Expired - Fee Related JP6317739B2 (ja) 2012-07-18 2013-07-18 短縮されたCD95−Fc変異体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015522107A Active JP6231562B2 (ja) 2012-07-18 2013-07-18 CD95−Fcアイソフォームの混合物を含む組成物

Country Status (18)

Country Link
US (5) US9315570B2 (cg-RX-API-DMAC7.html)
EP (4) EP3409686B1 (cg-RX-API-DMAC7.html)
JP (2) JP6231562B2 (cg-RX-API-DMAC7.html)
KR (1) KR102201694B1 (cg-RX-API-DMAC7.html)
CN (3) CN104640876A (cg-RX-API-DMAC7.html)
AU (2) AU2013291984B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015000732B1 (cg-RX-API-DMAC7.html)
CA (2) CA2878992C (cg-RX-API-DMAC7.html)
DK (2) DK2875045T3 (cg-RX-API-DMAC7.html)
ES (2) ES2674662T3 (cg-RX-API-DMAC7.html)
HK (1) HK1207095A1 (cg-RX-API-DMAC7.html)
IL (1) IL236659A (cg-RX-API-DMAC7.html)
MX (1) MX371430B (cg-RX-API-DMAC7.html)
NZ (1) NZ703546A (cg-RX-API-DMAC7.html)
RU (2) RU2648157C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201500134QA (cg-RX-API-DMAC7.html)
UA (1) UA116889C2 (cg-RX-API-DMAC7.html)
WO (2) WO2014013037A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2648157C2 (ru) * 2012-07-18 2018-03-22 Аподжиникс Аг КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ СМЕСЬ ИЗОФОРМ CD95-Fc
CN105393121B (zh) * 2013-04-29 2018-04-24 阿珀吉尼科斯股份公司 诊断癌症的方法
NO2776305T3 (cg-RX-API-DMAC7.html) 2014-04-23 2018-01-27
WO2015165973A1 (en) 2014-04-29 2015-11-05 Apogenix Gmbh Diagnostic anti-cd95l antibody
US9587215B2 (en) 2014-08-07 2017-03-07 General Electric Company Devices, systems and methods for automated transfer of a sample
US20160176921A1 (en) * 2014-12-22 2016-06-23 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
WO2020205662A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Inc. Ex vivo methods for producing a t cell therapeutic and related compositions and methods
JP2023504042A (ja) 2019-11-27 2023-02-01 ミスト セラピューティクス リミテッド ライアビリティ カンパニー 調節物質を使用した腫瘍反応性t細胞組成物の生成方法
WO2021119404A1 (en) * 2019-12-12 2021-06-17 Emd Millipore Corporation Intensified virus filtration using diafiltration buffer
BR112022016490A2 (pt) 2020-02-27 2022-10-11 Myst Therapeutics Llc Métodos para enriquecimento ex vivo e expansão de células t reativas tumorais e composições relacionadas das mesmas
CN115894706A (zh) * 2021-09-30 2023-04-04 北京康辰药业股份有限公司 靶向PD-L1和FasL的融合蛋白、核苷酸序列及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2253494A1 (en) * 1996-05-02 1997-11-13 Mochida Pharmaceutical Co., Ltd. Novel fas antigen derivative
EP0992243B1 (en) * 1996-10-31 2004-08-18 Mochida Pharmaceutical Co., Ltd. PROPHYLACTIC/REMEDIAL Fas antagonist for the prevention or treatment of GVHD
EP0990703B1 (en) * 1997-02-27 2008-06-04 Ono Pharmaceutical Co., Ltd. Novel polypeptide, dna encoding the same and use thereof
WO1999024069A1 (fr) * 1997-11-10 1999-05-20 Mochida Pharmaceutical Co., Ltd. Medicaments preventifs et therapeutiques pour des affections pulmonaires diffuses
EP2316951A1 (en) * 2001-01-17 2011-05-04 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1273297A1 (en) * 2001-07-06 2003-01-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Vitamin E for the treatment of diseases in which the binding of the transcription factor NF-KB and/or AP-1 to promoter target sites has a beneficial effect (eg AIDS, cardiac infarction)
DE602004022390D1 (de) * 2003-03-26 2009-09-17 Apogenix Gmbh Verbesserte fc-fusionsproteine
EP2004216A4 (en) * 2006-03-28 2012-02-01 Molecular Discovery Systems AGENT FOR THE TREATMENT OF HORMONO-DEPENDENT DISORDERS AND USES THEREOF
ES2371287T3 (es) * 2006-06-21 2011-12-29 Apogenix Gmbh Expresión diferencial de la citocina en cáncer humano.
US9309320B2 (en) * 2006-12-28 2016-04-12 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
WO2008101671A2 (en) * 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
EP2009022A1 (en) * 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
US8592557B2 (en) * 2008-06-17 2013-11-26 Apogenix Gmbh Multimeric TNF receptor fusion proteins and nucleic acids encoding same
EP2829550B1 (en) * 2009-01-09 2016-11-16 Apogenix AG Fusion proteins forming trimers
EP2456468A1 (en) * 2009-07-21 2012-05-30 Queen Mary and Westfield College Fas (apo-1, cd95) targeted platforms for intracellular drug delivery
BR112012013330A2 (pt) * 2009-12-02 2017-03-28 Acceleron Pharma Inc composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
RU2648157C2 (ru) * 2012-07-18 2018-03-22 Аподжиникс Аг КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ СМЕСЬ ИЗОФОРМ CD95-Fc
CN105393121B (zh) * 2013-04-29 2018-04-24 阿珀吉尼科斯股份公司 诊断癌症的方法

Similar Documents

Publication Publication Date Title
JP2015524403A5 (cg-RX-API-DMAC7.html)
JP2015525217A5 (cg-RX-API-DMAC7.html)
JP2015212284A5 (cg-RX-API-DMAC7.html)
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
EA201291362A1 (ru) Слитый белок против злокачественных новообразований
JP2012082206A5 (cg-RX-API-DMAC7.html)
WO2011123813A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
MX387465B (es) Marcas genéticas de transgenes y métodos de uso.
EP3372617A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
BRPI1010880A2 (pt) polipeptídeos de hormônio de crescimento e métodos de fazer e usar os mesmos.
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
PE20190845A1 (es) Metodos para determinar resistencia a terapia de receptor de androgeno
PH12012502272A1 (en) Biological materials related to her3
WO2013151670A3 (en) Modified polynucleotides for the production of nuclear proteins
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
JP2013527765A5 (cg-RX-API-DMAC7.html)
JP2015504052A5 (cg-RX-API-DMAC7.html)
EA201491277A1 (ru) Противораковый слитый белок
JP2018531624A5 (cg-RX-API-DMAC7.html)
PH12015500461A1 (en) Novel il-17a binding molecules and medical uses thereof
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
EP2589658A4 (en) PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN
HK1215441A1 (zh) 人血清白蛋白结合化合物及其融合蛋白